Pritam Saha Podder

OverviewAI-generated summary

Pritam Saha Podder's research focuses on chemotherapy-induced lymphatic dysfunction, with a specific emphasis on the effects of doxorubicin (DOX) treatment. He investigates the ryanodine receptor (RyR) as a potential therapeutic target to prevent lymphatic contractile dysfunction in breast cancer patients. This work addresses secondary lymphedema, a debilitating condition that affects cancer survivors and for which there are currently no FDA-approved pharmacological therapies targeting the underlying lymphatic contractile defects.

Podder earned a Bachelor of Pharmacy and has nine years of experience in the pharmaceutical industry. His doctoral training at the University of Arkansas for Medical Sciences is under the mentorship of Dr. Amanda Stolarz. He has contributed to research on animal models of lymphedema, resulting in a peer-reviewed publication with over 100 citations. His h-index is 3, with a total of 7 publications and 124 citations.

Metrics

• h-index: 3
• Publications: 7
• Citations: 124